Cabergoline is a dopaminergic ergoline derivative endowed with a potent and long-lasting PRL-lowering activity.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Cabergoline is the active ingredient of these drugs:
Australia Finland Ireland United Kingdom
Australia Austria Brazil Cyprus Finland
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):